tiprankstipranks
Trending News
More News >

SynAct Pharma’s Leadership Shows Confidence with Share Acquisition

Story Highlights
SynAct Pharma’s Leadership Shows Confidence with Share Acquisition

Don’t Miss TipRanks’ Half-Year Sale

An announcement from SynAct Pharma AB ( (SE:SYNACT) ) is now available.

SynAct Pharma AB announced that a majority of its board and management have acquired shares worth over SEK 1 million, demonstrating strong internal confidence in the company’s future. This move follows the company’s recent strategic focus on early intervention in autoimmune and inflammatory diseases, particularly rheumatoid arthritis, and host-directed treatment in viral infections, positioning SynAct for successful execution of its plans.

More about SynAct Pharma AB

SynAct Pharma AB is a clinical-stage biotechnology company that focuses on resolving inflammation through the selective activation of the melanocortin system. The company offers a broad portfolio of oral and injectable selective melanocortin agonists designed to induce anti-inflammatory and inflammation resolution activity, helping patients achieve immune balance.

Average Trading Volume: 229,498

Current Market Cap: SEK866.5M

See more data about SYNACT stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1